Rep. April McClain Delaney Sells Bio-Techne Corp (NASDAQ:TECH) Shares

Key Points

• Representative April McClain Delaney disclosed selling between $1,001 and $15,000 of Bio‑Techne (TECH) stock on April 8 (filing disclosed May 6) and executed several other $1k–$50k trades across multiple companies in late April.
• Bio‑Techne missed Q3 estimates, reporting $0.53 EPS vs. $0.55 consensus and $311.4M revenue vs. ~$316M, with management citing U.S. academic funding cuts and timing of large GMP/commercial shipments as headwinds.
• Market and corporate context: the company announced a $0.08 quarterly dividend (ex‑div May 18), shares were up about 7.4%, and analysts cut some price targets while the consensus rating remains a "Moderate Buy" (avg. target ≈ $66.77).

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Bio-Techne Corp NASDAQ: TECH. In a filing disclosed on May 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on April 8th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Service Corporation International NYSE: SCI on 4/30/2026.
• Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 4/30/2026.
• Purchased $1,001 - $15,000 in shares of STERIS NYSE: STE on 4/30/2026.
• Sold $1,001 - $15,000 in shares of Clean Harbors NYSE: CLH on 4/30/2026.
• Purchased $1,001 - $15,000 in shares of Transdigm Group NYSE: TDG on 4/29/2026.
• Purchased $1,001 - $15,000 in shares of Packaging Corporation of America NYSE: PKG on 4/29/2026.
• Purchased $1,001 - $15,000 in shares of Packaging Corporation of America NYSE: PKG on 4/24/2026.
• Purchased $1,001 - $15,000 in shares of Nasdaq NASDAQ: NDAQ on 4/24/2026.
• Sold $1,001 - $15,000 in shares of Fortune Brands Innovations NYSE: FBIN on 4/24/2026.
• Sold $15,001 - $50,000 in shares of C.H. Robinson Worldwide NASDAQ: CHRW on 4/24/2026.

Bio-Techne Stock Up 7.4%

Shares of NASDAQ:TECH opened at $50.91 on Friday. The stock has a market capitalization of $7.96 billion, a price-to-earnings ratio of 73.78, a price-to-earnings-growth ratio of 3.12 and a beta of 1.41. Bio-Techne Corp has a 1-year low of $45.12 and a 1-year high of $72.16. The company's fifty day moving average is $54.41 and its two-hundred day moving average is $59.54. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.08 and a current ratio of 4.49.

Bio-Techne (NASDAQ:TECH - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share for the quarter, missing analysts' consensus estimates of $0.55 by ($0.02). Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The firm had revenue of $311.42 million during the quarter, compared to analyst estimates of $316.11 million. During the same period last year, the business earned $0.56 EPS. The firm's revenue was down 1.5% on a year-over-year basis. Equities analysts anticipate that Bio-Techne Corp will post 1.73 EPS for the current year.

Bio-Techne Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Monday, May 18th will be issued a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, May 18th. Bio-Techne's dividend payout ratio is 62.75%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on TECH shares. Wells Fargo & Company dropped their price objective on shares of Bio-Techne from $76.00 to $62.00 and set an "overweight" rating on the stock in a report on Thursday. TD Cowen reaffirmed a "buy" rating on shares of Bio-Techne in a report on Tuesday, March 17th. UBS Group reaffirmed a "buy" rating and issued a $79.00 price objective (up from $70.00) on shares of Bio-Techne in a report on Thursday, February 5th. Stifel Nicolaus set a $50.00 price objective on shares of Bio-Techne in a report on Thursday. Finally, Evercore set a $50.00 price objective on shares of Bio-Techne in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $66.77.

Key Bio-Techne News

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Company is targeting ~100 basis points of margin expansion for Q4 while expecting organic growth to be approximately flat — investors may view cost/margin progress as a path to improved profitability. Q4 guidance article
• Positive Sentiment: Board declared a quarterly dividend of $0.08/share (payable May 29; ex-div May 18) — a modest income signal that can support investor sentiment. Dividend release
• Positive Sentiment: Company highlighted strong growth pockets in the quarter (mid-teens in Spatial Biology, ~50% growth in GMP proteins excluding fast‑track orders, mid-single-digit in proteomic instruments, continued double-digit growth from large pharma) — these growth vectors could underpin recovery if sustained. Q3 results
• Neutral Sentiment: Major sell‑side firms cut price targets but kept constructive ratings — Citigroup lowered its PT to $70 (still a Buy) and Wells Fargo trimmed to $62 (still Overweight). That reduces upside expectations but keeps analyst support. Citigroup note Wells Fargo note
• Negative Sentiment: Fiscal Q3 results disappointed: adjusted EPS $0.53 vs. ~$0.55 consensus and revenue $311.4M below estimates (~$316M), with reported and organic revenue down ~2% YoY — top‑line softness drove the initial selloff. Reuters coverage Earnings summary
• Negative Sentiment: Management cited demand headwinds (U.S. academic funding cuts) and timing of large GMP/commercial shipments and prior-year fast-track orders as reasons for the shortfall — these are external and timing risks that could keep near-term growth uneven. Headwinds explained

Hedge Funds Weigh In On Bio-Techne

Several large investors have recently bought and sold shares of TECH. Danske Bank A S acquired a new position in Bio-Techne during the 4th quarter valued at about $29,000. eCIO Inc. acquired a new position in Bio-Techne during the 4th quarter valued at about $30,000. Measured Wealth Private Client Group LLC acquired a new position in Bio-Techne during the 3rd quarter valued at about $32,000. iSAM Funds UK Ltd acquired a new position in Bio-Techne during the 3rd quarter valued at about $33,000. Finally, EverSource Wealth Advisors LLC increased its stake in Bio-Techne by 506.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company's stock valued at $35,000 after buying an additional 562 shares during the period. Institutional investors and hedge funds own 98.95% of the company's stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Bio-Techne Company Profile

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.